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The hemodynamic and electrophysiologic alterations in-
duced by ionic contrast agents during cardiac angiog-
raphy are well described. Recently nonionic contrast 
agents have become available for cardiac angiography. 
To evaluate the safety of these new agents, a double-
blind randomized study was performed comparing a new 
nonionic agent (iopamidol) with a commonly used ionic 
contrast agent (Renografin-76). Eighty-one patients 
undergoing left ventriculography and coronary angi-
ography were included; 41 received iopamidol and 40 
received sodium meglumine diatrizoate (Renografin-76). 
After left ventriculography, there was a decrease in 
the arterial pressure with both contrast agents. How-
ever, the severity and the duration of hypotension were 
both significantly greater with Renografin-76 compared 
with the new non ionic agent (p < 0.001). After selective 
injections of the coronary arteries, electrocardiographic 
Numerous animal and human studies (1-18) have docu-
mented the deleterious effects of ionic contrast media on 
the myocardium immediately after contrast ventriculog-
raphy and coronary angiography, Decreases in systemic ar-
terial pressure and myocardial contractility and alterations 
in the ventricular pressure-volume relation after the use of 
ionic contrast agents are well described ( I A-IS), Although 
the intensity and duration of these changes are known. the 
mechanisms responsible for these alterations of myocardial 
function remain controversial. The contribution of various 
factors. such as contrast-induced hypocalcemia. osmolality 
of the agent or a direct effect of the contrast molecule or 
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analysis demonstrated that the increase in the QT in-
terval (p < 0.0002) and the changes in both the ST 
segment and T wave amplitude (p < 0.001) were sig-
nificantly greater in the Renografin-76 group compared 
with the iopamidol group. During coronary angiogra-
phy, 8 of the 40 patients receiving Renografin-76 re-
quired temporary pacing for sinus pauses of 2.5 seconds 
or more, and 2 of the 40 also developed ventricular 
fibrillation. None of the 41 patients receiving iopamidol 
had these complications. 
This report demonstrates that the electrocardio-
graphic changes, the severity and duration of hypoten-
sion and the incidence of serious arrhythmias are sig-
nificantly greater with Renografin-76 than with iopamidol. 
Thus, this new nonionic agent appears to enhance the 
safety of cardiac angiography. 
(J Am Coli Cardiol 1985;5:250-8) 
anion. to these hemodynamic and physiologic alterations is 
unclear (5.7.11-13.15.19-27). 
Sodium meglumine diatrizoate (Renografin-76) is a com-
monly used contrast agent for cardiac angiography. Several 
studies (1.8.15.17.20) have demonstrated the adverse ef-
fects of this standard ionic agent on myocardial function. 
metabolism and electrophysiology. Metrizamide was the 
first commercially available nonionic contrast agent. Animal 
and human studies (15.20.28-32) demonstrated that its ad-
verse hemodynamic and physiologic effects were signifi-
cantly less than those of ionic agents. In addition. it reduced 
the discomfort experienced by the patient during intravas-
cular angiography (32). However, metrizamide is unstable 
in aqueous solution; therefore, it must be reconstituted from 
the lyophilized form immediately before intravascular in-
jection. Recently, nonionic contrast agents that are hydro-
lytic ally stable have been developed and are being evaluated 
for use in coronary angiography (33-40). 
The purpose of this investigation was to evaluate one of 
these new nonionic agents. iopamidol. in human subjects 
in a randomized double-blind study. The electrocardio-
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graphic and hemodynamic alterations induced by this new 
agent during left ventriculography and selective coronary 
angiography were measured and compared with those In-
duced by Renografin-76. 
Methods 
Patient selection. All patients undergoing left ventric-
ulography and selective coronary angiography at the San 
Francisco Veterans Administration Medical Center were el-
igible for this study except for I) patients with a history of 
adverse reactions to contrast media or iodine compounds, 
2) patients with bleeding disorders, 3) patients with creat-
inine clearance below 25 mllmin, and 4) patients receiving 
intravascular or orally absorbable contrast material within 
I week of the study. 
The study was of a randomized double-blind design for 
comparison of iopamidol and sodium meglumine diatrizoate 
(Renografin-76) as the contrast agent used for left ventric-
ulography and selective coronary angiography. Iopamidol 
and Renografin-76 both contain 37% iodine. The viscosities 
of iopamidol and Renografin-76 are similar at 37°C, 9.4 cp 
and 8.4 cp, respectively. 
Procedure. All patients received oral diazepam ( 10 mg) 
as premedication. No medications were withheld before the 
catheterization. No patient received atropine. Electrocar-
diographic leads I and II were monitored continuously dur-
ing the procedure. An 8F USCI sheath was placed in the 
femoral artery. For the treatment of bradyarrhythmias or 
complete heart block which may develop during coronary 
angiography, a temporary pacing catheter was inserted through 
a femoral venous sheath and positioned at the apex of the 
right ventricle. For asystolic episodes lasting 2.5 seconds or 
more, pacing was performed at 60 beats/min until the pa-
tient's intrinsic rhythm returned. The left ventriculogram 
was performed using a 7F Cordis high flow pigtail catheter; 
0.5 ml/kg of contrast medium was injected at 12 mils. The 
amount of contrast agent injected for the left ventriculogram 
was 40.5 :i: 5.7 ml in the iopamidol group and 37.4 :i: 4.9 
ml in the Renografin-76 group. Left ventricular volumes 
and ejection fraction were calculated using a calibrated grid 
and the method of Kennedy et al. (41). The electrocardio-
gram, left ventricular pressure and femoral artery pressure 
were recorded continuously for 6 seconds before the left 
ventriculogram and for the first 2 minutes after the injection. 
In all patients, the left ventriculogram preceded the selective 
injections of the right and left coronary arteries. Similarly, 
the electrocardiogram and aortic pressure were recorded 
before and for the first 2 minutes after the first selective 
injection of the right and left coronary arteries. All record-
ings were made at a strip chart speed of 100 mm/s. There 
were no test injections of contrast agent preceding the left 
ventriculogram or the first selective injection of the coronary 
arteries. Immediately after the procedure, each patient was 
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asked to grade on a 0 to 10 scale subjective feelings of pain 
and warmth that occurred during and after the contrast 
injections. 
The cineangiograms were reviewed by an independent 
observer with regard to quality of contrast, definition and 
opacification of coronary vessels and were graded as poor, 
adequate, good or excellent. 
Blood for determination of urea nitrogen and serum cre-
atinine was obtained at baseline (before angiography) and 
at 24 and 48 hours after the procedure. If the values were 
abnormal at 48 hours, these tests were repeated I week after 
angiography and, if abnormal, repeated until the values 
returned to baseline levels. The protocol was approved by 
the Human Research Committees of the University of Cal-
ifornia and the Veterans Administration Medical Center at 
San Francisco. Informed written consent was obtained from 
each patient. 
Statistics. All hemodynamic and electrocardiographic 
variables were analyzed by repeated measures analysis of 
variance using Tukey's tests to determine whether there was 
a difference between the changes induced by the two contrast 
agents (42). The unpaired t test was used to determine whether 
there was a difference between the hemodynamic and 
electrocardiographic variables of the iopan;idol and Reno-
grafin-76 groups at baseline. The chi-square test was used 
to compare discrete variables. The nonparametric variables 
such as cineangiographic quality and subjective response of 
the patients to the contrast agent were compared using the 
Mann-Whitney test. The data in the text and tables are 
presented as mean :i: I standard deviation. The mean values 
:i: I standard error are shown in the figures. 
Results 
Patient characteristics. The study group consisted of 
81 male patients. Seventy-nine patients underwent left ven-
triculography and selective coronary angiography for symp-
toms of ischemic heart disease and two underwent the pro-
cedure for evaluation of valvular heart disease. Forty-one 
patients received iopamidol and 40 received Renografin-76. 
The patient characteristics in these two groups are listed 
in Tahle I. A coronary lesion was considered significant if 
75% or more of the cross-sectional luminal area of the vessel 
was obstructed. There was no significant difference between 
the two groups in the number of patients with significant 
left main lesions and with no, one, two or three vessel 
disease. Two patients receiving Renografin-76 had aortic 
valve disease; one had significant aortic regurgitation re-
quiring valve replacement and the other had mild aortic 
stenosis. One patient in the iopamidol group had significant 
aortic stenosis requiring valve replacement. In each group, 
there was one patient with mild mitral regurgitation. 
Indexes ollefi ventricular function are also listed in Table 
I. There was no significance difference in ejection fraction, 
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Table 1. Characteristics of Patients 
No. of patients 
Age (yr) 
Severity of CAD 
(no. of patients with "'75';' obstruction) 
No ves,el disease 
One vessel disea,e 
Two vessel disea,e 
Three vessel disease 
Left main lesion 
Valvular heart disease 
(no. of patients) 
Aortic stenosis/aortic regurgitation 
Mitral regurgitation 
Left ventricular function 
Ejection fraction (%) 
Left ventricular end-diastolic 
volume index (011/01') 
Left ventricular end-diastolic 
pressure (mm HI') 
lopamidol 
41 
57 :t: 10 
5 
7 
X 
21 
7 
59 :t: 10 
XO :±: 19 
13 :t: 6 
Renografin-76 
40 
60 :±: 7 
4 
7 
7 
22 
II 
2 
62 :±: 13 
75 :t: IX 
12 :t: 6 
p Value 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
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Data are presented a, mean :±: I standard deviation. CAD = coronary artery disease: NS = no significant 
difference between the iopamidol and Renografin-76 groups. 
left ventricular end-diastolic volume index and baseline left 
ventricular end-diastolic pressure between the two groups. 
The medications received hy the patients hellJre the an-
xioxraphic study are listed in Tahle 2. There was no sig-
nificant difference in the types of medications prescribed 
for the patients in the two groups. 
The haseline (hellJre contrast medium) systolic arterial 
pressure, le.lf ventricular end-diastolic pressure and electro-
cardioxraphic data for these two xroups ol paticnts arc 
xivcn in Tahle 3. There was no significant difference in any 
of these measurements at baseline between the two groups. 
Hemodynamic alterations. The baseline (before con-
trast medium) systolic arterial pressure was 146 ± 22 mm 
Hg in the Renografin-76 group and 141 ± 24 mm Hg in 
the iopamidol group (p = NS). After left ventriculography, 
there was a decrease in the arterial pressure in both groups 
(Fig. 1). The average decrease in systolic pressure was 
48 ± 14 mm Hg in the Renografin-76 group and 19 ± II 
mm Hg in the iopamidol group (p < 0.001). The duration 
Table 2. Medications Administered Immediately 
Before Angiography 
Long-acting nitrates 
Beta-adrenergic blocking agents 
Calcium channel blocking agents 
Digoxin 
Antiarrhythmic agents 
Diuretic drugs 
Antihypertensive agents 
Data represent number of patients. 
lopamidol 
30 
35 
21 
5 
5 
16 
2 
Renografin-76 
33 
35 
16 
4 
14 
3 
of the decrease in systolic pressure (decrease in systolic 
pressure > 10% of control) was 45 ± 25 seconds in the 
Renografin-76 group compared with 9 ± 10 seconds in the 
iopamidol group (p < 0.00 I). Thus, not only was the de-
crease in arterial pressure greater after Renografin-76 but 
also the duration of these changes was significantly longer 
compared with iopamidol. The change in left ventricular 
end-diastolic pressure induced by ventriculography is also 
shown in Figure 1. After injection of Renografin-76, the 
average increase in end-diastolic pressure at 90 seconds after 
the ventriculogram was 9 ± 7 mm Hg compared with 1 ± 
5 mm Hg for iopamidol. This difference was highly sig-
nificant (p < 0.001). 
Thc systolic artcrial prcssurc durinx the control period 
and alter the .first selcctive injection ()l the riXht and le.li 
coronary arteries is shown in Fixure 2. There was no sig-
nificant difference between the two groups in the arterial 
pressure during the control period. After selective injection 
of either the right or the left coronary artery, arterial pressure 
did not change in the iopamidol group but decreased sig-
nificantly in the Renografin-76 group (p < 0.001). 
Electrocardiographic changes. Figure 3 compares the 
electrocardiographic changes induced by selective contrast 
injections of the left and right coronary arteries and left 
ventriculography in the Renografin-76 and iopamidol groups. 
Data are shown for the control period and for the 60 second 
period after the contrast injection. With selective left coro-
nary injection, there was a marked prolongation of the QT 
interval. from 394 ± 32 to 482 ± 56 ms, in the Renografin-
76 group (p < 0.001), but only a slight increase, from 386 
± 33 to 393 ± 36 ms, in the iopamidol group (p = NS). 
A repeated measures analysis of variance showed that there 
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Table 3. Baseline Hemodynamic and Electrocardiographic Variable~ 
lopan1ldol l{~no~ralil1- 76 p Value 
Systolic arterial pressure (111111 H~) 
Left ventricular end-diastolic 
141 • 24 
I~ + 6 
NS 
NS 
pressure (mm H~) 
OT interval (ms) .lX6 -I .' I ~X6 + 2X 
O.lJX + 0.14 
(l.1l + Il'i 
14 1 1.2 
NS 
NS 
NS 
NS 
RR interval (seconds) 
ST segment displacement (mm) 
T wave amplitude (mm) 
100 + 0 II 
(l.O + (U 
1.6 + 1.6 
All electrocardiographic variahles were measured in lead II One millivolt = 10 n1l11. NS no slgnilieant 
difference hetween the iopamidol and Renogralil1-76 groups. Data are presented as mean + 1 standard deviation. 
was a significant difference in the prolongation of the QT 
interval produced by two contrast agents (p < 0.0001). At 
the end of the 60 second period. there was still a significant 
increase in the QT interval in the Renografin-76 group com-
pared with the control value (p < 0.001). and a significant 
difference between the two contrast agent groups (p < 0.00 I). 
Selective injections of the right coronary artery produced a 
similar change in the QT interval; the difference between 
Figure l. The systolic arterial pressure (top) is shown for control 
(time 0) and for the 2 minute period after left ventriculography 
for the 41 iopamidol (£---£) and 40 Renogratin-76 ( ________ ) 
patients. The left ventricular end-diastolic pressure (bottom) is 
also shown for the control period and after the left ventriculogram. 
The left ventriculogram was performed immediately after the con-
trol values (time 0). The data are presented as mean::+:: I standard 
error. II p < 0.05 iopamidol versus Renogratin-76: * p < (J.OI 
iopamidol versus Renogratin-76: ~ p < 0.005 iopamidol versus 
Renogratin-76: :j: p < 0.00 I iopamidol versus Renogratin-76: 'I- p 
< 0.05 versus control; H p < 0.0 I versus control: * p < 0.005 
versus control: ** p < 0.001 versus control. 
..J 
< a: 
160 
~ w ..... 140 
II: II: en 
< ~ ~ 120 
~ :3 E 
..JII: o Q. ...... 100 
l-
I/) 
> 
I/) 80 
25 
20 
15 
10 
5 
o 
LEFT VENTRICULOGRAPHY 
i I * T I ___ r-----
. " \\.** l",-"'--'t 
.. t'i··- t * 
** t 
** ** 
---t"" 
** 
** 
** .. + 
+ t + 
" + t---t---t-----t------f 
~~~~--+-~~I~'~~ 
o 20 40 60 90 120 
TIME (seconds) 
the two contrast agents was again highly significant (p < 
0.0002). 
There Ims no significlInt chllnge ill the RR illlerva/ in 
the ioparnidol-treated patients after selective injections of 
either the right or left coronary artery. However, in the 
patients receiving Renogrann-76 there was a significant in-
crease in the RR interval from O. 9K :+:: 0.15 to 1.32 :+:: 0.46 
seconds after left coronary angiography (p < 0.0(1) and a 
similarincreasefromO.9K:+:: O.15to 1.26:+:: 0.44 seconds 
after right coronary angiography (p < 0.(01) (Fig. 3). The 
QRS duration was (l.OK :+:: OJ)I second in the Renografin-
Figure 2. The systolic arterial pressures immediately before (time 
0) and for the :2 minute~ after the tirst selective contrast inject jon 
of the right coronary artery (top) and the len coronary artery 
(bottom) are plotted. The data arc presented as mean ± I standard 
error. £---£ represent the values in the jopamidol group and 
............. in the Renogratin-76 )!roup. Symbols for probability (p) 
values as in Figure I. 
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agents, 19 of the 40 patients treated with Renografin-76 
developed an intraventricular conduction defect with the 
duration of the QRS complex greater than 0.10 second, 
whereas only 3 of the 41 iopamidol-treated patients had 
prolongation of the QRS complex (p < 0.01). 
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Figure 3. The changes in the QT intervals, RR intervals, ST 
segments and T wave amplitudes induced by the contrast injections 
of the left coronary artery (left) and right coronary artery (middle) 
and by left ventriculography (right) are shown. The data are pre-
sented as mean ;:t:: I stal1dard error. 6.---6. represent the changes 
after iopamid!,>1 injection and ~ after Renografin-76 injec-
tion. Measurements and symbols for probability (p) values as in 
Figures I and 2. 
••
~
-t,' 'i- ' ._-t,-.-i- -
+
++
++
++
+ ~ + + +
+ + +~'±"t'i"i--''t---''i---'i--''i
....,
"' ...
I
.
.
> Ina: '0
cu
Z
....,
..... - .
...
UJ
_ I
w
::;)
I-
."'"
:l
( 0
.....
...
.1. I.1--1---~---1.--.1---.l
+ + "+ +-_.......------.,.
.,
.*
••
.*
~ I
.
± I A A
lACC Vol. 5, No.2 
f'cbruary 1985: 250--8 
With riRht coronar\' arter\' injectiolls or RelloRrajill-76. 
electrocardiographic analysis of lead II demonstrated sig-
nificant ST segment depre~sion from 0.0 ± 0.5 to -0,9 
± I, I Iilm (p < 0.00 I) and marked T wave inversion from 
an amplitude of 1.4 ± 1,2 to - 2,2 ± 2,6 mm (p < (LOOI) 
(Fig, 3), At the end of 60 seconds. there was still a signif-
icant decrease in T wave amplitude compared with the con-
trol value in the Reriografin-76 group (p < (U)OI). With 
iopamidol. there was ST segment depression from 0,0 ± 
0,3 to - 0,3 ± 0,6 mm at 5 seconds after the contrast 
injection (p < 0,0(5). but there was no significant change 
in T wave amplitude, A repeated measures analysis of var-
iance showed that there was a significant difference in the 
ST segment and T wave amplitude response for the two 
contrast agents (p < 0,05 and p < (U)OOI. respectively), 
With the left corollary injections there was a significant 
elevation in the ST segment and a significant increase in T 
wave amplitude in lead II with Renografin-76, With iopam-
idol. there was no significant change in these two variables 
(Fig, 3). 
Serious arrhythmias. Two of the patients in the Ren-
ografin-76 group developed ventricular fibrillation during 
selective injection of the right coronary artery: the arrhyth-
mia was immediately treated with electrical cardioversion 
and there were no iate sequelae in either patient. There were 
no episodes of ventricular tachycardia or fibrillation in the 
iopamidol group. 
There was 0 siRnijiCllflt hut hrier tJecreose ill the hearl 
rate immediately after injections of I:Jbth the right and left 
coronary arteries with Renografin-76 (Fig. 3). whereas with 
iopamidol there was no significant change in the heart rate. 
All patients in this study had a temporary pacing catheter 
placed in the right ventricle which wa~ used for periods of 
asystole lasting 2.5 seconds or more. Eight of the 40 patients 
receiving Renografin-76 required pacing during the coronary 
injections. However. none of the 41 patients in the iopam-
idol group was paced during the procedure. This difference 
in the development of serious bradyarrhythmias during coro-
nary injections is significant (p < 0.(1). 
Chest pain. It is not uncommon for patients to experi-
ence transient chest pain and feelings of warmth during and 
immediately after selective contrast injections of the coro-
nary arteries and during left ventriculography. After the 
procedure. each patient was asked to grade these subjective 
feelings of pain and warrhth that occurred during angiog-
raphy. Thirty-three of the 40 patiertts receiving Renografin-
76 had no chest pain during the irltravascular bolus injection 
for the left ventriculogram. Likewise. 37 of the 41 patients 
in the iopamidol group had no pain. There was no significant 
difference between the two groups for chest pain induced 
by the left ventriculogram. However. on a scale of 0 to 10 
for the sensation of warmth associated with the left ven-
triculogram. the mean score was 7.0 ± 2.5 for the Reno-
grafin-76 group and 4.2 ± 2.3 for the iopamidol group; 
this difference was significant (p < (l05). 
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DuriflR selective COroflOr\' aflMioMraphv. 25 of the 40 
patients treated with Renografin-76 had chest pain. whereas 
only II of the 41 iopamidol-treated patients had pain (p < 
0.0(5). In the Renografin-76 group. the mean score for pain 
during the selective coronary angiography was 3.1 ± 3.0 
and the score for warmth was 2.8 ± 2.7. In comparison. 
the mean scores for the iopamidol group were 0.8 ± 1.6 
and 1.1 ± 2.0. respectively. The differences for both pain 
and warmth during coronary angiography were significant 
(p < (LOS). In most patients. the chest pain associated with 
the contrast injection was very transient and required no 
treatment. However. 13 of the patients treated with Reno-
grafin-76 required nitroglycerin for their chest pain asso-
ciated with coronary angiography, Only five of the iopam-
idol-treated patients had chest pain requiring treatment with 
nitroglycerin during the study. 
Other side effects. Two of the patients receiving Ren-
ografin-76 developed nausea and vomiting after contrast 
injection. None of the patients in the iopamidol group had 
gastrointestinal symptoms during or after the procedure. 
There was flO difference in the mean creatinine clearance 
hetweefl the two groups; the mean value for the calculated 
creatinine clearance was 81 ± 23 ml/min in the patients 
treated with Renografin-76 and 85 ± 25 mllmin in the 
iopamidol-treated patients. Two patients receiving Reno-
grafin-76 had deterioration of their renal function after an-
giography. as defined by a 0.5 mg/dl increase in serum 
creatinine. In these patients, the creatinine increased from 
1.3 and 1.2 mg/dl (control) to 2.3 and 2.6 mg/dl. respec-
tively, 48 hours after angiography. In the iopamidol group. 
only one patient had a similar increase in serum creatinine 
from 1.2 to 1.7 mg/dl. In all three patients. the deterioration 
in renal function was transient. 
Quality of cineangiograms. Both contrast agents con-
tain 370 mg iodine/ml and produced very good to excellent 
visuali/.ation of the coronary anatomy. We could not detect 
a difference in the cineangiographic quality of the left ven-
triculograms and the selective coronary angiograms between 
iopamidol and Renografin-76. 
Discussion 
Safety of cardiac angiography. Morbidity and mortal-
ity associated with selective coronary angiography and left 
ventriculography have decreased in the last decade (43-45). 
Many of the remaining complications are directly related to 
the contrast medium. There is a decrease in systemic ar-
terial pressure and an increase in left ventricular end-dia-
stolic pressure immediately after an intravascular bolus 
injection of an ionic contrast medium for the left ventric-
ulogram (5.7-9.13.31.34.35). Selective coronary injections 
of these ionic agents are associated with bradyarrhythmias. 
prolongation of the QRS complex. increase in the QT in-
tervaL marked shifts in the ST segment and T wave changes 
( 1-3, 10.29.31.34,46). Development of contrast agents that 
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are less toxic to the myocardium than these standard ionic 
agents should enhance the safety of angiographic procedures. 
Animal studies (15.28-31.38) have shown that the new 
nonionic agents arc associated with fewer hemodynamic and 
electrocardiographic changes compared with ionic contrast 
media. Measurements of myocardial contractility have shown 
that these new agents have a small positive inotropic effect 
as opposed to the negative inotropic effects of the ionic 
agents (15.20.33.35). These non ionic agents have been 
evaluated in several human studies (32,34,39.40), and their 
results corroborate the findings of the animal studies, sug-
gesting that these new agents are safer. 
This is the first large study that compares iopamidol and 
Renografin-76 in human subjects in a double-blind random-
ized fashion. Our data demonstrate that the hemodynamic 
and electrocardiographic changes induced by contrast left 
ventriculography and coronary angiography were signifi-
cantly less when the nonionic agent. iopamidol. was com-
pared with a standard ionic contrast medium. The incidence 
and severity of bradyarrhythmias and systemic hypotension 
were greater with Renografin-76 compared with iopamidol. 
Prolongation of the QT interval. widening of the QRS com-
plex and ST and T wave changes were also significantly 
greater in the Renografin-76 group compared with the io-
pam idol group. These findings indicate that iopamidol is 
less toxic to the myocardium compared with Renografin-
76. 
Ventricular fibrillation. Ventricular fibrillation is one 
of the most serious complications associated with coronary 
angiography and is directly associated with injections of 
contrast agent. Although there is no direct relation between 
development of ventricular fibrillation and changes in the 
QT interval. prolongation of the QT interval is considered 
a risk factor for ventricular arrhythmia (46-49). In this 
study, the increase in the QT interval was significantly greater 
with Renografin-76 than with iopamidol (p < 0.0(02). If 
there were a direct relation between prolongation of QT 
interval and ventricular fibrillation. one might expect a higher 
incidence of ventricular fibrillation in the Renografin-76 
group. In our study, 2 of the 40 patients in the Renografin-
76 group developed ventricular fibrillation during selective 
coronary angiography, whereas none of the 41 patients 
receiving iopamidol had this complication. Although the 
number of patients in this study is too small to determine 
the true incidence of ventricular fibrillation for each contrast 
agent. our data suggest that the incidence of ventricular 
fibrillation may be higher for Renografin-76 than for io-
pamidol. Using Renografin-76 as the contrast agent. the 
incidence in our laboratory of ventricular tachycardia-
fibrillation is 1.5%. This was determined in 260 consecutive 
cases petformed after the completion of this double-blind 
study. 
Heterogeneity of depolarization and repolarization within 
adjacent areas of the myocardium is one of the proposed 
JACC Vol. 5. No.2 
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mechanisms of contrast-induced ventricular fibrillation. Franz 
et al. (50) measured indexes of depolarization and repolar-
ization during the coronary injections of iopamidol and Ren-
ografin-76 in dogs. They found that Renografin-76 caused 
a significantly greater prolongation of the monophasic action 
potential compared with iopamidol. Their findings also sug-
gest that the risks of ventricular arrhythmias are higher with 
Renografin-76 than with iopamidol. 
Biochemical data. We (17) and Visioli et al. (18) have 
demonstrated that contrast ventriculography with Reno-
grafin-76 induces changes in myocardial metabolism. Re-
cently (51). we have investigated the myocardial metabolic 
effects of iopamidol and have shown that the decrease in 
myocardial lactate extraction that occurs after injection of 
Renografin-76 did not occur with this new nonionic agent. 
Using [1- '4Cllactate as a tracer, we measured the amount 
of lactate released by the myocardium before and after an 
injection of Renografin-76 and iopamidol. After injection 
of Renografin-76, there was a 54 ± 38% increase in myo-
cardial lactate release, whereas after iopamidol there was 
no significant change in the amount of lactate released (52). 
These biochemical data suggest that contrast angiography 
with the standard ionic agents induces myocardial cellular 
ischemia and that the newer non ionic agent. iopamidoJ, does 
not produce these changes. 
Factors influencing contrast medium toxicity. In ad-
dition to the contrast ion or molecule, there are a number 
of other important differences between these two contrast 
agents, such as osmolality and cation composition and con-
tent. The contribution of these factors to the electrocardio-
graphic and hemodynamic differences observed in this study 
is unclear. Many reports (5.7,12,13,15,19,20,28,35,53) have 
indicated that the toxicity of a contrast agent is directly 
related to the osmolality. The osmolality of Renografin-76 
( 1,680 mosm/kg) is approximately twice that of iopamidol 
(796 mosm/kg) (34,36,38). Recently, an ionic contrast agent 
(ioxaglate) has been developed which has an osmolality 
similar to iopamidol (20,31,38,53). Tragardh and Lynch 
(31) compared the effects of ioxaglate, diatrizoate (Reno-
grafin-76) and two nonionic compounds during coronary 
angiography in animals. Their study demonstrated that both 
nonionic agents were associated with fewer hemodynamic 
and electrophysiologic changes than the new ionic low os-
molality contrast agent. Although osmolality plays an im-
portant role in contrast agent toxicity, the study by Tragardh 
and Lynch (31) suggests that it is not the only factor. The 
cation composition and content of the contrast agent also 
appear to be important factors (15,19,20,22,23,46,54-56). 
lopamidol has negligible amounts of sodium compared with 
190 mEq/liter in Renografin-76. Renogratin-76 has no cal-
cium and iopamidol contains only negligible amounts of 
calcium. Contrast agents with varying sodium and calcium 
contents have been evaluated (15,20,22,23,56). Although 
the addition of calcium appears to decrease the toxicity, the 
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entire cardiodepressant effect of the contrast medium is not 
eliminated. Further studies are needed to elucidate the mech-
anisms for the differences in the toxicity we observed be-
tween iopamidol and Renografin-76. 
Clinical implications. This study has shown that the 
incidence of malignant bradyarrhythmias and the severity 
and duration of hypotension after left ventriculography and 
coronary angiography is significantly less with iopamidol 
than with the standard ionic agent. Renogratin-76. The in-
cidence of ventricular fibrillation may also be less with 
iopamidol compared with Renografin-76. Other electrocar-
diographic and hemodynamic variables measured in this 
study indicate that iopamidol is less toxic to the myocar-
dium. Therefore. this nonionic agent appears to increase the 
safety of cardiac angiography. In addition. the discomfort 
experienced by the patient was considerably less with io-
pamidol compared with the ionic agent. The cineangio-
graphic quality of the two contrast agents was similar. In-
creasing the safety of cardiac angiography without 
compromising excellent cineangiographic results makes this 
new nonionic contrast agent. iopamidol. superior to the 
standard ionic agents. 
The cost of this new nonionic contrast medium will prob-
ably be greater than the standard ionic contrast agents. Fur-
ther studies are needed to address the cost/benefit ratio of 
these new agents. Although the costs may preclude their 
use in all patients undergoing angiography. we believe that 
patients at high risk. such as those with impending myo-
cardial infarction, unstable angina, impaired ventricular 
function or recurrent ventricular arrhythmias. will benefit 
greatly through the use of these nonionic agents in cardiac 
angiography. 
We expre" appreciation to Mary Parks and Lucinda Li,ton. RN for tech-
nical as,istance in the Cardiac Catheterization Lahoratory. Gunnard Modin. 
BS ror assi,tance in the stati,tical analy,i, and Patricia Paulson for ,ec-
retarial assistance. 
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